Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ITU512 in healthy participants and patients with sickle cell disease
PACTR202508611698393Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Aug 2024
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 3
01
Overview
Phase 1 trial of ITU512 in sickle cell disease (SCD) (2 arms), sponsored by Novartis. Started Aug 2024; status: recruiting.
02
Drugs
ITU512
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202508611698393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202508611698393.